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The association between gout and nephrolithiasis in men: The
Health Professionals’ Follow-Up Study. Approximately 10 mil-
lion adults in the United States have experienced the passage
of a kidney stone, and up to 5 million have been diagnosed
with gout by a physician. Previous reports have suggested that
gout increases the risk for the development of kidney stones,
but there are no prospective data. We used data from a cohort
of 51,529 male health care professionals to examine the inde-
pendent association between gout and kidney stone disease.
In a cross-sectional analysis of gout and kidney stone disease
reported on the 1986 baseline questionnaire, the prevalence
of kidney stone disease was almost twofold higher in men with
history of gout compared to those without (15% vs. 8%). After
adjusting for age and body mass index (BMI), a history of gout
remained significantly associated with kidney stone disease
(OR 1.88; 95% CI 1.68 to 2.11). We then prospectively exam-
ined the risk of incident kidney stones in men with and without
a confirmed diagnosis of gout after excluding men who reported
a history of kidney stone disease or gout on the baseline ques-
tionnaire. A confirmed diagnosis of gout increased the multi-
variate relative risk of incident kidney stones (RR 2.12; 95%
CI 1.22 to 3.68). In contrast, a history of kidney stone disease
was not associated with increased risk of gout (RR 1.05; 95%
CI 0.54 to 2.07). In conclusion, a history of gout independently
increases the risk for incident kidney stones in men. Physicians
should provide dietary counseling, such as increasing fluid in-
take and decreasing salt consumption, to subjects with gout in
addition to other risk factors, such as family history of kidney
stones, in order to decrease the likelihood of stone formation.
Over 500,000 Americans suffer from kidney stone dis-
ease every year [1], with an estimated cost for treatment
(hospitalization, procedures, and medical visits) exceeding
$4 million per 1000 patients treated per year [2]. Gout,
a painful inflammatory arthritis induced by the deposi-
tion of monosodium urate monohydrate crystals in tis-
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sues [3], has been linked with kidney stone disease in
several previous studies [4–7]. Yu and Gutman [4] re-
ported a 15% to 22% prevalence of kidney stone disease
among individuals with gout, greater than the 12% life-
time risk reported in the general population [1, 5]. Using
data from a nationally representative sample of United
States adults, we noted a threefold higher prevalence of
kidney stone disease among individuals with a history of
gout [6]. Even after controlling for current age and body
mass index (BMI), as well as gender, race, and hyperten-
sion, individuals with gout were still 49% more likely to
report a history of kidney stones [6].
Because these previous investigations were cross-sec-
tional, it cannot be determined whether the higher preva-
lence of gout among men and women with kidney stones
was due to risk factors such as dietary habits (fluid, salt,
and protein intake) or medication use such as thiazides
[8–13], which may be altered after the diagnosis of gout
or kidney stones and influence the subsequent develop-
ment of the other. Moreover, these cross-sectional analy-
ses cannot discern whether gout precedes the symptom-
atic kidney stones or kidney stones precede the onset of
gout. Although the association between gout and risk
of kidney stone disease appears widely accepted in the
medical literature, no prospective studies have examined
whether gout independently predicts the risk of kidney
stones or quantified the magnitude of the association
between gout and risk of incident kidney stones.
Therefore, we used data from a cohort of 51,529 male
health care professionals to prospectively investigate the
independent association between gout and incident kid-
ney stones.
METHODS
Study population
The Health Professionals’ Follow-up Study (HPFS)
is a cohort study of 51,529 male dentists, optometrists,
osteopaths, pharmacists, podiatrists, and veterinarians
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who were 40 to 75 years old in 1986. Information on
diet, medical history, and medication use was obtained
from questionnaires mailed biennially to the HPFS parti-
cipants. After a maximum of six mailings of the biennial
questionnaire for each follow-up period, the follow-up
exceeds 90%. The men were predominantly white, al-
though no exclusions were made on the basis of race.
Ascertainment of gout
Information on gout was first collected on the 1986
questionnaire and new cases were reported on subse-
quent questionnaires. In 2001, the first supplementary
form was mailed to confirm the self-reported case of
gout between 1986 and 1998 using the American College
of Rheumatology survey criteria for acute arthritis of
primary gout [14, 15]. Subjects who reported gout on
the 1986 questionnaire were not sent the supplementary
questionnaire. There were 1681 cases of physician-diag-
nosed self-reported gout between 1986 and 1998. Of
these, the gout questionnaires were sent to the 1332
cases who were alive in 2001. The response rate to the
supplementary questionnaire was 79% and 67% of self-
reported gout cases were confirmed. Cases of gout were
considered confirmed if the subject reported six or more
of the 11 gout criteria.
Ascertainment of kidney stones
Beginning in 1986, the questionnaires inquired about
history of kidney stones and date of diagnosis. Subjects
who reported kidney stones on the baseline 1986 ques-
tionnaire were not sent a supplementary questionnaire.
When a kidney stone was reported for the first time in 1988
or later, a supplementary form was mailed to ascertain
the date of occurrence, symptoms, and family history
of kidney stones. In order to be considered a case, a
participant had to report associated pain or hematuria on
the supplementary questionnaire. Thus, asymptomatic
stones, such as those noted during a routine radiologic
examination, were not considered cases. To confirm the
validity of the self-report, we obtained the medical re-
cords from a random sample of 60 cases, which confirmed
a kidney stone in 97% [16].
Covariates
Medical history, dietary habits, weight, and medication
use were collected at baseline and on follow-up question-
naires. BMI (kg/m2) was calculated from the self-reported
height and updated weight. A subject was considered to
have hypertension if he reported physician-diagnosed
hypertension on any questionnaire. Diet was assessed
in 1986, 1990, and 1994 using a semiquantitative food-
frequency questionnaire that inquired about the average
use of 130 foods and beverages during the previous
year. Nutrient intake was computed from the reported
frequency of consumption of each specified unit of food
or beverage and from published data on the nutrient
content of the specified portions [17]. Information was
also collected on supplemental vitamins and minerals,
including calcium, either alone or in multivitamin prepa-
rations. The reproducibility and validity of this dietary
questionnaire have been previously reported [17].
Statistical analysis
The association between prevalent kidney stone dis-
ease and gout was assessed in 1986 using a cross-sectional
analysis. Age-adjusted relative risks were computed us-
ing the Mantel-Haenszel pooled-estimate technique [18].
Logistic regression was used to control for the following
baseline covariates simultaneously: age (5-year intervals),
BMI (five categories), history of hypertension (yes/no),
thiazide use (yes/no), supplemental calcium (0 mg/day,
1 to 100 mg/day, 101 to 500 mg/day, and 500 mg/day),
alcohol consumption (eight categories), and quintiles of
dietary intake of calcium, animal protein, potassium, so-
dium, sucrose, magnesium, vitamin B6, and total fluid.
We performed two separate prospective analyses to
determine (1) the relative risk for incident kidney stone
disease occurring between 1988 and 1998 in men with a
confirmed diagnosis of gout after 1986 and (2) the rela-
tive risk for incident gout occurring between 1988 and
1998 in men with initial kidney stone disease after 1986.
All subjects who reported kidney stones or gout on the
baseline 1986 questionnaire were excluded from these
prospective analyses. Person-time was allocated to his-
tory of kidney stone disease or gout according to the 1988
questionnaire and then updated with each subsequent
questionnaire. If gout and kidney stones were reported
on the same questionnaire, we could not discern which
disease occurred first. Therefore, we repeated the pro-
spective analyses with the exclusion of men who reported
both gout and kidney stones on the same follow-up ques-
tionnaire. Person-years of follow-up were calculated
from the date of the return of the 1986 questionnaire to
the date of the first diagnosis, death, or January 31, 1998,
whichever came first.
Categorical variables were compared using the chi-
square test and continuous variables were compared us-
ing the t test. Age-adjusted and multivariate-adjusted
relative risks were computed using Cox proportional haz-
ards models. Participants were censored at the end of
a 2-year cycle if they reported kidney stones or gout
(depending on the analysis) or died during that time
period. The following updated covariates were included
in all multivariate Cox regression models: age (5-year
intervals), BMI (five categories), history of hypertension
(yes/no), thiazide use (yes/no), supplemental calcium (0
mg/day, 1 to 100 mg/day, 101 to 500 mg/day, and 500
mg/day), alcohol consumption (eight categories), and
quintiles of dietary intake of calcium, animal protein,
potassium, sodium, sucrose, magnesium, vitamin B6, and
total fluid. All P values are two-tailed and 95% confi-
dence intervals were calculated for all relative risks.
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Table 1. Characteristics of the Health Professionals’ Follow-up
Study participants by reported gout on 1986 baseline questionnaire
Gout  Gout  P value
Number % 2655 (5%) 47062 (95%)
Age yearsa 59.9 (9.1) 54.4 (9.8) 0.001
Body mass index, kg/m2a 27.0 (3.9) 25.5 (3.3) 0.001
Dietary intake mg/day
Animal protein g/day 69.4 (18.6) 67.6 (17.8) 0.001
Calcium 748 (282) 799 (306) 0.001
Supplemental calcium 98.9 (266) 96.6 (261) 0.6
Sodium 3262 (1206) 3261 (1134) 0.7
Potassium 3526 (722) 3441 (722) 0.001
Magnesium 352 (82.6) 354 (83.6) 0.2
Sucrose g/day 44.2 (17.6) 45.6 (16.9) 0.001
Caffeine 224 (236) 239 (250) 0.002
Vitamin B6 9.2 (26.5) 8.6 (24.8) 0.6
Alcohol g/day 14.3 (19.2) 11.2 (15.2) 0.001
Fluid intake L/day 2.0 (0.8) 1.9 (0.8) 0.001
Hypertension 1321 (50%) 9799 (21%) 0.0013
Kidney stones 394 (15%) 3539 (8%) 0.0013
Current thiazide use 637 (24%) 4178 (9%) 0.0013
aValues expressed as means (standard deviation)
RESULTS
Cross-sectional analysis of self-reported gout and
kidney stones
Among the 51,529 HPFS participants, 49,717 provided
information on kidney stone disease, gout, and diet on
the 1986 questionnaire. Overall, 3933 (8%) subjects re-
ported a history of kidney stones and 2655 subjects (5%)
reported a history of gout at baseline. The characteristics
of the subjects by history of reported gout in 1986 are
shown in Table 1. Men with a history of gout were slightly
older (59.9 years vs. 54.4 years), had a higher body mass
index (27.0 kg/m2 vs. 25.5 kg/m2) and reported a higher
intake of alcohol compared to those without gout (14.3
g/day vs. 11.2 g/days). In addition, men with gout were
more likely to have hypertension (50% vs. 21%; P 
0.001), report current thiazide use (24% vs. 9%; P 
0.001), and have a history of kidney stone disease (15%
vs. 8%; P 0.001) compared to men without gout. How-
ever, no substantial differences in reported dietary intake
of sodium, magnesium, or vitamin B6 were noted be-
tween the two groups.
After adjusting for age and BMI, gout was associated
with an increased risk of kidney stone disease (RR 1.88;
95% CI 1.68 to 2.11). Further adjustment for baseline
dietary factors, thiazide use, and history of hypertension
did not substantially change the results (RR 1.77; 95%
CI 1.57 to 1.99).
Prospective analysis
Incident kidney stones according to confirmed diagno-
sis of gout. After excluding men who reported a history
of kidney stones or gout on the baseline 1986 question-
naire, 43,984 remained eligible for the prospective analy-
ses. After 402,330 person-years of follow-up, 1332 inci-
dent cases of kidney stones occurred between 1986 and
1998. Participants with a confirmed diagnosis of gout had
an increased risk for subsequent incident kidney stones
in the age-adjusted (RR 2.06; 95% CI 1.19 to 3.57) and
multivariate-adjusted models (RR 2.12; 95% CI 1.22 to
3.68) compared to those without gout (Table 2). Because
gout and kidney stones may have been first diagnosed
during the same time period, we repeated the analysis
after excluding men who newly reported both gout and
kidney stones during the same time period. After exclud-
ing three men who were diagnosed with gout and kidney
stone disease during the same time period, there was a
positive association between gout and risk of incident
kidney stones, but the results were no longer statistically
significant (RR 1.69; 95% CI 0.90 to 3.17).
Incident gout according to history of kidney stone dis-
ease. Between 1986 and 1998, there were 661 confirmed
cases of incident gout. A history of kidney stone disease
was not associated with increased risk of incident gout
in the age-adjusted (RR 1.07; 95% CI 0.56 to 2.07) or
multivariate-adjusted models (RR 1.05; 95% CI 0.54 to
2.03) (Table 3). When we repeated the analyses after
excluding three participants who reported both gout and
kidney stone disease on the same follow-up question-
naire, no significant association was noted between his-
tory of kidney stone disease and risk of incident gout in
the multivariate-adjusted model (RR 0.72; 95% CI 0.32
to 1.60).
DISCUSSION
In this large prospective study of men, a history of
gout increased the risk of incident kidney stone disease
by approximately twofold, even after controlling for age,
dietary factors, BMI, and thiazide use. However, we
noted no association between history of kidney stone
disease and risk of incident gout. To our knowledge,
no previous studies have prospectively investigated the
association between gout and kidney stone disease.
Individuals with gout typically have persistently acidic
urine due to a defect in the renal production of ammonia,
which may be inherent or secondary to tubular damage
from urate crystal deposition [19]. Individuals with gout
have a higher risk for uric acid stone formation due to
the low urine pH, which creates an environment favor-
able for uric acid precipitation [19]. Gout may also in-
crease the risk for calcium oxalate stone formation, the
most common type of kidney stones [1, 20]. The precipi-
tation of uric acid in the presence of a low urine pH may
create heterogeneous nuclei for calcium oxalate crystalli-
zation [21], and reducing urinary uric acid excretion with
allopurinol has been shown to decrease the risk of cal-
cium oxalate stone formation [22].
The association between gout and kidney stone dis-
ease has been demonstrated in several previous cross-
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Table 2. Age-adjusted and multivariate adjusted relative risks for kidney stone disease by confirmed diagnosed gouta
Person-years Kidney stone cases Age-adjusted RR Multivariate-adjusted RRb
Confirmed gout  400,187 1319 1.00 (reference) 1.00 (reference)
Confirmed gout  2143 13 2.06 (1.19–3.57) 2.12 (1.22–3.68)
a Subjects who reported gout or kidney stones on the 1986 questionnaire were excluded
b The multivariate model included age (5-year intervals), body mass index (five categories), history of hypertension (yes/no), thiazide use (yes/no), supplemental
calcium (0 mg/day, 1 to 100 mg/day, 101 to 500 mg/day, and 500 mg/day), alcohol consumption (eight categories), and quintiles of dietary intake of calcium, animal
protein, potassium, sodium, sucrose, magnesium, vitamin B6, and total fluid
Table 3. Age and multivariate adjusted relative risk for confirmed diagnosis of gout by history of kidney stonesa
Person-years Confirmed gout cases Age-adjusted RR Multivariate-adjusted RRb
Kidney stones  402,352 652 1.00 (reference) 1.00 (reference)
Kidney stones  4825 9 1.07 (0.56–2.07) 1.05 (0.54–2.03)
a Subjects who reported gout or kidney stones on the 1986 questionnaire were excluded
b The multivariate model included age (5-year intervals), body mass index (five categories), history of hypertension (yes/no), thiazide use (yes/no), supplemental
calcium (0 mg/day, 1 to 100 mg/day, 101 to 500 mg/day, and 500 mg/day), alcohol consumption (eight categories), and quintiles of dietary intake of calcium, animal
protein, potassium, sodium, sucrose, magnesium, vitamin B6, and total fluid.
sectional studies. Among 1258 patients with primary
gout, 22% reported a history of kidney stones [5], a
prevalence substantially higher than the 12% lifetime
risk reported in the general population [1, 5]. Using data
from the third National Health and Nutrition Examina-
tion Survey, we noted a substantially higher prevalence
of kidney stone disease among individuals with physi-
cian-diagnosed gout compared to the general population
(14% vs. 6%) [6]. Even after controlling for age, gender,
race, and thiazide use, individuals with gout were 49%
more likely to report a history of kidney stone disease
compared to those without gout [6].
The limitations of this study deserve mention. The
lack of an association between kidney stone disease and
risk of incident gout may have been due to the small
number of incident gout cases among men with kidney
stones diagnosed after 1986, which limited our power to
examine this association. In addition, due to the older
age of the HPFS cohort, it is possible that the exclusion
of subjects who reported kidney stone disease or gout
on the baseline 1986 questionnaire may have led to a
selection bias because older men with kidney stone dis-
ease may be less likely to develop gout compared to
younger men with kidney stone disease. Yu and Gutman
[4] reported that 50% of the 280 men with both primary
gout and kidney stone disease experienced the passage
of a kidney stone or gravel prior to the onset of gout.
However, among subjects age 40 years and older, kidney
stone disease preceded the development of gout in only
35%. The mean age when these subjects first passed a
kidney stone was 44 years, while the mean age of gout
onset was 46 years [4]. We did not adjust for allopurinol
use because we did not have this information from all
subjects. Subjects with gout are frequently treated with
allopurinol, which could reduce incident kidney stone
formation; thus, this study may have underestimated the
risk of kidney stones in subjects with gout. Allopurinol
may also be prescribed to men with uric acid or calcium
oxalate stones in order to prevent further stone forma-
tion [21], and its use would consequently decrease the
risk for developing symptomatic gout [22]. However, the
majority of first time kidney stone formers in the HPFS
cohort are not treated, so it is unlikely that the null
association between kidney stone disease and risk of
gout was due to allopurinol use.
The strengths of this study include the large size and
the participants’ high level of education and strong inter-
est in health. Because the cohort was male and predomi-
nantly white, the results may not be generalizable to
women or nonwhite individuals. The study was limited
by the fact that asymptomatic kidney stones were not
considered kidney stone cases. Nonetheless, a subject’s
report of a kidney stone was unlikely to be related to
the prior diagnosis of gout by a physician. Thus, any
misclassification of kidney stones would likely have been
nondifferential and would not explain the positive associ-
ation between gout and risk of incident kidney stones.
CONCLUSION
Men with gout have a twofold increased risk for devel-
oping incident kidney stones compared to men without
gout. Both kidney stones and gout are common disorders
among men. Thus, it may be prudent for physicians to
warn an individual with both gout and an additional risk
factor, such as family history, of the increased risk for
kidney stone formation and suggest dietary modifications
such as increasing fluid intake and decreasing salt con-
sumption. In addition, this study provides further evi-
dence that kidney stone disease should be viewed as a
systemic metabolic disorder.
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